About Clever Culture Systems
Clever Culture Systems is a leader in microbiology technology driven by artificial intelligence, specializing in automated culture plate reading solutions for pharmaceutical manufacturing and clinical laboratories. The company's flagship product, APAS Independence (Automated Plate Assessment System), is a world-leading in-vitro diagnostic instrument that automates the imaging, analysis, and interpretation of agar culture plates following incubation. Designed by microbiologists for microbiologists, the system uses advanced imaging and sophisticated AI algorithms to identify, interpret, and count microbial growth on culture media, processing up to 200 plates per hour without manual intervention. The technology serves pharmaceutical quality control laboratories for environmental monitoring and clinical microbiology labs for applications including urine screening, infection control, and antimicrobial susceptibility testing. APAS Independence has achieved regulatory clearances from the US FDA, CE Marking under IVDR, MHRA registration in the UK, and ARTG listing in Australia. The system integrates with laboratory information management systems (LIMS) to provide real-time reporting, enhanced data integrity, and complete traceability through digital plate images. The company's technology is scientifically validated and referenced in over 25 publications in leading academic journals, offering laboratories improved efficiency, standardization, and staff satisfaction by automating time-consuming, repetitive culture plate reading tasks.
Clinical Focus
Medical conditions and clinical areas addressed by Clever Culture Systems.
Who It Serves
Milestones & Awards
Recent Milestones
Achieved CE Marking under new IVDR regulations. Multiple regulatory clearances across US, Europe, UK, and Australia.
Awards & Recognition
Described as 'world-leading' and 'best-in-class' technology for automated culture plate reading
Key Partnerships
Company Details
- Headquarters
- Adelaide, SA, Australia
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Cognoa
Cognoa is an early childhood development and pediatric behavioral health company developing digital diagnostics and therapeutics. Their flagship product, Canvas Dx, is the first FDA-authorized AI-powered diagnostic solution for autism in children ages 1.5-6 years, enabling diagnosis within days instead of months or years.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.